| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 04/30/2009 | US20090111755 Methods for the use of inhibitors of antigen presentation by mhc class ii molecules |
| 04/30/2009 | US20090111741 Method for treating and/or preventing drug seeking behavior |
| 04/30/2009 | US20090111733 Par-4 related methods and compositions |
| 04/30/2009 | US20090111106 Vector System |
| 04/30/2009 | US20090110745 Over-the-counter vitamin/nutriceutical formulation that provides neuroprotection and maintains or improves cognitive performance in alzheimer's disease and normal aging |
| 04/30/2009 | US20090110737 Orally Disintegrating Powder Comprising Cilostazol and Mannitol |
| 04/30/2009 | US20090110735 Controlled release formulations |
| 04/30/2009 | US20090110729 Solid oral compositions based on s-adenosyl methionine and/or nadh and process for obtaining them |
| 04/30/2009 | US20090110722 Composition |
| 04/30/2009 | US20090110706 Pain relief composition and utilization thereof |
| 04/30/2009 | US20090110682 Antibody Having Inhibitory Effect on Amyloid Fibril Formation |
| 04/30/2009 | DE202008005433U1 Kauzusammensetzung Kauzusammensetzung |
| 04/30/2009 | DE102005056558B4 Kombinationspräparate enthaltend physiologische Zellmembran-Bestandteile Combination products containing physiological cell membrane components |
| 04/30/2009 | CA2711839A1 Method of treatment with potentised stereoisomer of glutamate |
| 04/30/2009 | CA2704008A1 New tetracyclic compounds |
| 04/30/2009 | CA2703647A1 Process for preparing o-desmethylvenlafaxine |
| 04/30/2009 | CA2703614A1 Splice variants of gdnf and uses thereof |
| 04/30/2009 | CA2703472A1 Methods for treating substance dependence |
| 04/30/2009 | CA2703471A1 Pyrazinyl amide t-type calcium channel antagonists |
| 04/30/2009 | CA2703465A1 Synthesis and crystalline forms of cb-1 antagonist/inverse agonist |
| 04/30/2009 | CA2703461A1 Compounds of 2,3-dihydro-benzofuran |
| 04/30/2009 | CA2703458A1 Phenylpyrrolidine compounds |
| 04/30/2009 | CA2703453A1 Indoline compounds |
| 04/30/2009 | CA2703335A1 Inhibitors of caspase i-dependent cytokines in the treatment of neurodegenerative disorders |
| 04/30/2009 | CA2703157A1 Amino arylsulfonamide compounds and their use as 5-ht6 ligands |
| 04/30/2009 | CA2703138A1 Purine derivatives useful as pi3 kinase inhibitors |
| 04/30/2009 | CA2702447A1 New phenyl-substituted piperazino-dihydrothienopyrimidines |
| 04/30/2009 | CA2702126A1 Heterocycle amide t-type calcium channel antagonists |
| 04/30/2009 | CA2701594A1 Heterocycle phenyl amide t-type calcium channel antagonists |
| 04/30/2009 | CA2700210A1 Condensed compounds with activity at estrogen receptors |
| 04/29/2009 | EP2053050A1 Dihydrochalcone similar to aspalathin and method for its manufacture |
| 04/29/2009 | EP2053042A1 Pyridine compounds for the treatment of prostaglandin mediated diseases |
| 04/29/2009 | EP2053041A2 1,3,5-Trisubstituted 2(1H)-pyridones as AMPA receptor inhibitors useful for the treatment of eg Parkinson's disease |
| 04/29/2009 | EP2053038A1 Aminoalcohol derivative and immunosuppressant containing the same as an active ingredient |
| 04/29/2009 | EP2052738A1 THERAPEUTIC AGENT FOR ACCELERATION OF SPINAL NERVE REPAIR COMPRISING GHRELIN, DERIVATIVE THEREOF OR SUBSTANCE CAPABLE OF ACTING ON GHS-R1a AS ACTIVE INGREDIENT |
| 04/29/2009 | EP2052719A1 Curative drug for neurodegenerative diseases |
| 04/29/2009 | EP2052717A1 Multiparticulate O-desmethylvenlafaxine salts and uses thereof |
| 04/29/2009 | EP2052251A1 Combination 5-ht7 receptor antagonist and serotonin reuptake inhibitor therapy |
| 04/29/2009 | EP2052085A2 Methods for modulating set and uses thereof |
| 04/29/2009 | EP2051991A1 Cardioprotective compounds |
| 04/29/2009 | EP2051971A1 Process for the preparation of pramipexole base and/or its salts |
| 04/29/2009 | EP2051967A1 Benzimidazole derivatives useful in treatment of vallinoid receptor trpv1 related disorders |
| 04/29/2009 | EP2051961A1 Novel isoindol derivatives as ep4 receptor agonists |
| 04/29/2009 | EP2051958A1 Phenyl-prenyl-ether derivatives for the treatment of cognitive, neurodegenerative or neuronal diseases or disorders |
| 04/29/2009 | EP2051735A2 Conjugates comprising a gaba- or glycine compound, pharmaceutical compositions and combinations thereof as well as their use in treating cns disorders |
| 04/29/2009 | EP2051715A2 Modulators of muscarinic receptors |
| 04/29/2009 | EP2051712A2 Modulators of muscarinic receptors |
| 04/29/2009 | EP2051706A1 Transmucosal administration of 2,3-dimethoxy-5-methyl-6-(10- hydroxydecy l)-1,4-benzoquinone |
| 04/29/2009 | EP1838707B1 Novel pyrrolodihydroisoquinolines as pde10 inhibitors |
| 04/29/2009 | EP1828154B1 Phenyl-piperazin methanone derivatives |
| 04/29/2009 | EP1791813B1 Pentafluorosulfanylphenyl-substituted benzoylguanidines, method for the production thereof, their use as a medicament or diagnostic agent, and a medicament containing these compounds |
| 04/29/2009 | EP1784177B1 Formulation for l-tryptophane comprising carbidopa/benserazide |
| 04/29/2009 | EP1727555B1 Production of hop extracts having oestrogenic and antiproliferative bioactivity |
| 04/29/2009 | EP1720844B1 Pyrrolidino-1,2-dicarboxy-1-(phenylamide)-2-(4-(3-oxo-morpholino-4-yl)-phenylamide) derivatives and related compounds for use as inhibitors of coagulation factor xa in the treatment of thrombo-embolic diseases |
| 04/29/2009 | EP1687631B1 Methods for identifying compounds involved in the phosphoinositide-mediated signalling and use thereof in the manufacture of medicaments |
| 04/29/2009 | EP1670769B1 Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof |
| 04/29/2009 | EP1651592B1 Novel dibenzo[b,f]oxepine-10-carboxamides and pharmaceutical uses thereof |
| 04/29/2009 | EP1572204B1 Synergistic compositions with analgesic properties comprising n-acylated 4-hydroxyphenylamine derivatives |
| 04/29/2009 | EP1552822B1 Patch |
| 04/29/2009 | EP1539764B1 Aryl-substituted diazabicycloalkanes as nicotinic acetylcholine agonists. |
| 04/29/2009 | EP1509207B1 Pharmaceutical composition containing oxcarbazepine and having a controlled active substance release |
| 04/29/2009 | EP1485347B1 Hif hydroxylase inhibitors for use in the treatment of anaemia |
| 04/29/2009 | EP1454136B1 Methods and means for influencing intracellular communication and intracellular organelle transport |
| 04/29/2009 | EP1446379B1 Aryl aniline beta-2 adrenergic receptor agonists |
| 04/29/2009 | EP1446125B1 Thieno-(1,3)-oxazin-4-ones with lipase inhibiting activity |
| 04/29/2009 | EP1438288B1 Substituted thioacetamides |
| 04/29/2009 | EP1416937B1 Prophylactic and therapeutic use of hydroxysteroids |
| 04/29/2009 | EP1296652B1 Topical pharmaceutical formulations and methods of treatment |
| 04/29/2009 | EP1257582B1 Method for inhibiting angiogenesis using molecules that enhance plasmin formation or prolong plasmin activity |
| 04/29/2009 | EP1218509B1 Fibroblast growth factor-like polypeptides |
| 04/29/2009 | EP1066286B1 Heterocyclo-substituted imidazopyrazine protein tyrosine kinase inhibitors |
| 04/29/2009 | CN101421394A Expansion of neural stem cells with LIF |
| 04/29/2009 | CN101421304A Affinity regions |
| 04/29/2009 | CN101421303A Improved protofibril selective antibodies and the use thereof |
| 04/29/2009 | CN101421300A Novel sodium channel |
| 04/29/2009 | CN101421299A Peptide vaccine for inducing production of anti-amyloid- -peptide antibody |
| 04/29/2009 | CN101421281A Substituted imidazo[2,1-b]thiazole compounds and their use for producing drugs |
| 04/29/2009 | CN101421280A Substituted-dihydro[1,4]oxazino[2,3,4-hi]indazole derivatives as 5-hydroxytryptamine-6 ligands |
| 04/29/2009 | CN101421264A Heterocyclic compounds suitable for treating disorders that respond to modulation of the serotonin 5HT6 receptor |
| 04/29/2009 | CN101421263A Novel crystalline compounds |
| 04/29/2009 | CN101421243A Aryloxyethylamine compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor |
| 04/29/2009 | CN101421240A Aminomethyl pyridine derivatives, method for preparing same and therapeutic use thereof |
| 04/29/2009 | CN101421239A Bicyclic tetrahydropyrrole compounds |
| 04/29/2009 | CN101421237A Metabotropic glutamate receptor-potentiating soindolones |
| 04/29/2009 | CN101420983A Methods and compositions comprising supramolecular constructs |
| 04/29/2009 | CN101420982A Dry direct compression fast disintegrating tablet |
| 04/29/2009 | CN101420971A Therapeutic target molecules for the development of novel medicaments for degenerative diseases |
| 04/29/2009 | CN101420964A Compositions comprising human embryonic stem cells and theirderivatives, methods of use, and methods of preparation |
| 04/29/2009 | CN101420954A The use of deferiprone and methods to treat and/or prevent friedreich ataxia resulting from intracellular mishandling of iron |
| 04/29/2009 | CN101420953A Mazindol combination in the treatment of attention deficit/hyperactivity |
| 04/29/2009 | CN101420947A Alpha-2-delta ligands for non-restorative sleep |
| 04/29/2009 | CN101420944A Novel pharmaceutical compositions for optimizing substitution treatments and extending the pharmacopoeia to global treatment of addictions |
| 04/29/2009 | CN101420943A Chewing composition containing coenzyme Q10 |
| 04/29/2009 | CN101418046A TAT protein transduction modified NEP1-40 fusion protein and use thereof |
| 04/29/2009 | CN101417964A Use of compounds for the elevation of pyruvate dehydrogenase activity |
| 04/29/2009 | CN101417129A Gabapentin analogues for fibromyalgia and other related disorders |
| 04/29/2009 | CN101417126A New use of OMI protein and coding gene thereof |
| 04/29/2009 | CN101417123A Use of therapeutic human albumin for the preparation of a drug for the treatment of patients suffering from cognitive disorders |
| 04/29/2009 | CN101417097A Traditional Chinese medicine combination for treating cervical vertebra disease |
| 04/29/2009 | CN101417085A Medicine for treating nerve dizziness |